OREXIGEN THERAPEUTICS INC's ticker is and the CUSIP is 686164AB0. A total of 3 filers reported holding OREXIGEN THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $3,550,000 | -25.6% | 10,000,000 | 0.0% | 0.43% | -29.4% |
| Q3 2017 | $4,769,000 | -5.1% | 10,000,000 | 0.0% | 0.61% | -22.3% |
| Q2 2017 | $5,025,000 | -8.2% | 10,000,000 | 0.0% | 0.78% | -16.2% |
| Q1 2017 | $5,475,000 | +82.5% | 10,000,000 | 0.0% | 0.93% | +54.4% |
| Q4 2016 | $3,000,000 | +13.2% | 10,000,000 | 0.0% | 0.60% | +20.8% |
| Q3 2016 | $2,650,000 | – | 10,000,000 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERBACK ASSET MANAGEMENT LLC | 20,871,000 | $12,627,000 | 3.02% |
| Telemetry Investments, L.L.C. | 9,426,000 | $5,473,000 | 1.86% |
| Partner Investment Management, L.P. | 437,000 | $261,000 | 0.43% |
| PFM Health Sciences, LP | 16,788,000 | $10,034,000 | 0.30% |
| Verition Fund Management LLC | 2,066,000 | $1,210,000 | 0.23% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 20,664,000 | $12,519,000,000 | 0.21% |
| Cheyne Capital Management (UK) LLP | 500,000 | $298,000 | 0.16% |
| SYMPHONY ASSET MANAGEMENT LLC | 2,244,000 | $1,314,000 | 0.14% |
| WOLVERINE ASSET MANAGEMENT LLC | 6,000,000 | $3,498,000 | 0.08% |
| PALISADE CAPITAL MANAGEMENT, LP | 1,743,000 | $1,030,000 | 0.03% |